Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | Sacituzumab govitecan and NKTR-214 plus nivolumab for bladder cancer

Arjun Balar • 6 Mar 2019
GU Cancers 2019
Bladder Cancer Genitourinary Cancer Antibodies Nivolumab NKTR-214 Sacituzumab govitecan
PIVOT-02

Speaking from the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Arjun Balar, MD, from NYU Langone Health Perlmutter Cancer Center, New York City, NY, discusses the promising results from the Phase I study with sacituzumab govitecan (NCT01631552), and the PIVOT-02 study (NCT02983045) looking at the novel combination of NKTR-214 with nivolumab for treating-bladder cancer resistant to checkpoint inhibitors.

More from Arjun Balar

2:58
EV-201: enfortumab vedotin for cisplatin-ineligible bladder cancer
Arjun Balar • 18 Feb 2021
2:22
KEYNOTE-057: extended follow-up of pembrolizumab in bladder cancer
Arjun Balar • 18 Feb 2021
4:12
Systemic versus intravesical therapy for NMIBC
Arjun Balar • 18 Feb 2021
3:16
KEYNOTE-057 update: pembrolizumab for high-risk NMIBC patients
Arjun Balar • 8 Mar 2019

Related Videos

10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
3:07
Serum thymidine kinase 1 as a predicative biomarker in prostate cancer
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals